Health Robotics' Announces Memorial Care's [CA] 57% Savings From Ameridose's Switch to i.v.STATION Robot

Aug 12, 2013, 08:00 ET from Health Robotics

BOZEN, Sud-Tirol, Italy, August 12, 2013 /PRNewswire/ --

Health Robotics recently announced that Memorial Care Health System in Long Beach released to Health Robotics' User Group an ROI study focused on 57% average savings as a result of insourcing Sterile Compounding patient doses on the i.v.STATION Robot, compared to its prior equivalent costs with Ameridose.

Ed Wong,Director of Pharmacy at Memorial Care's Miller Hospitalstated: "Just as an example of the i.v.STATION Robot cost benefits at Memorial Care, for a single active pharmaceutical principle [Oxytocin], we documented savings of $73,874 (or 60%) over a 21 month period between August 2011 and April 2013. i.v.STATION utilized standard commercially-available Baxter Viaflex Bags and APP drug vials of 10ml and 30ml, with the Robot preparing dilutions of 13,876 patient doses of 1 Liter Bags LR, and 3,955 patient doses of 500ml IV Bags at 0.9% NS, at an internal cost of $49,954 compared to the prior and equivalent Ameridose expense of $123,828."

Under the current leadership of William Churchill from Brigham & Women's Hospital and Paul Bush from Duke University Medical Center, Health Robotics' User Group holds teleconferences once per quarter for its members, in addition to an annual meeting during ASHP Midyear, which provides an ideal forum for progressive Health-System Pharmacies to compare experiences, best practices, and cost savings, on how to improve Sterile Compounding quality and lower costs.

Gaspar DeViedma, Health Robotics' Executive Vice President stated: "I'm very proud that i.v.STATION continues on its undeterred path to collect under-12 month ROIs and cost justifications from both Academic and Community Health-Systems pharmacies in North America, following prior similar published reports from Brigham & Women's Hospital [MA], LeeSar Compounding Services [FL], Allegiance Health [MI], Candler Hospital [GA], St. Joseph Hospital [GA], and several others.

These documented benefits are especially important in the wake of the recent legislative attempts in Massachusetts [ground zero for 2012 deadly contamination affecting patients nationwide],, and the appalling results of FDA's 2013 inspection reports at 50 sites:

About Health Robotics:

Founded in 2006 and now reaching 80% total IV Robots market share in the world [including over 90% the Oncology Robots global market], Health Robotics is the undisputed leading supplier of life-critical intravenous medication robots, providing almost 500 hospital installations in 5 continents with the only fully-integrated Robotics-based technology, IV Workflow, and manual compounding software automation solutions. Health Robotics' second generation products [i.v.STATION, i.v.SOFT, and i.v.STATION ONCO] have been found [through scientific and peer-reviewed studies[1],[2],[3]] to greatly contribute to ease hospitals' growing pressures to improve patient safety[1], increase throughput, and contain costs[1],[ 3]. Through the effective and efficient production of sterile, accurate, tamper-evident and ready-to-administer IVs, Health Robotics' medical devices and integrated workflow solutions help hospitals eliminate life-threatening drug[1] and diluent[1] exchange errors, improve drug potency[2], decrease other medical mistakes and sterility risks, work more efficiently[1],[ 3], reduce waste and controlled substances' diversion, reduce pharmacy technician upper-limb injuries[3], and diminish the gap between rising patient volume/acuity and scarce nursing and pharmacy staff. For more information, please visit:


1. Impact of Robotic Antineoplastic Preparation on Safety, Workflow, Costs. Seger, Churchill, Keohane, Belisle, Wong, Sylvester, Chesnick, Burdick, Wien, Cotugno, Bates, and Rothschild. Brigham & Women's Hospital, Massachusetts College of Pharmacy, and Harvard Medical School. Journal of Oncology Practice, Nov. 2012, Volume 8, number 6.

2. Validation of an automated method for compounding monoclonal antibody patient doses: case studies of Avastin®, Remicade®, and Herceptin®. Peters, Capelle, Arvinte, van de Garde. St. Antonius Hospital. mAbs January 2013, Volume 5, Issue 1.

3. Comparing the upper limb disorder risks associated with manual and automated cytotoxic compounding. McLeod, Zochowska, Leonard, Crow, Jacklin, Dean, Franklin. Imperial College Healthcare NHS Trust. European Journal of Hospital Pharmacy April 2012.

For additional information, please contact:
Luisa Celeghin

SOURCE Health Robotics